University of California San Francisco

Mehta
Neil
Mehta
MD

Associate Professor of Medicine

General Hepatology and Liver Transplantation

Department of Medicine

Address

400 Parnassus Avenue, #A740
San Francisco, CA 94117
United States

Phone: 415-502-2569
Fax: 415-476-0659

Biography

Dr. Neil Mehta is a gastroenterologist and specialist in liver transplantation.

In his research, Mehta examines liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include outcomes for patients who undergo liver transplantation and cardiac iron overload in patients with chronic liver disease. He frequently lectures in the community and at the university on these subjects.

At the UCSF School of Medicine, Mehta supervises the training of residents as well as fellows in both gastroenterology and liver transplant medicine. He also delivers lectures on liver disease to UCSF medical students studying metabolism and nutrition.

Mehta earned his medical degree at UCSF and completed a residency in internal medicine at the University of Pennsylvania. He completed fellowships in gastroenterology and liver transplantation at UCSF.

Education

Institution Degree Dept or School End Date
University of California, San Francisco M.D. Medicine 2006

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine - Gastroenterology
American Board of Internal Medicine - Transplant Hepatology

Collaboration Interests

I am interested in:

  • policy change

Clinical Expertise

Alcoholic Liver Disease

Autoimmune Hepatitis

Cirrhosis

Drug-Induced Hepatitis

Fulminant Hepatic Failure

Hemochromatosis

Hepatitis B

Hepatitis C

Hepatocellular Carcinoma (Liver Cancer)

Liver Transplantation

Living Donor Liver Transplantation

Nonalcoholic Fatty Liver Disease

Polycystic Liver Disease

Primary Biliary Cirrhosis

Primary Sclerosing Cholangitis

Clinical Trials

  1. National Liver Cancer Screening Trial (NCT06084234)
    Related Conditions: Liver Cancer, Cirrhosis, Hepatitis B, Cancer, General, Hepatocellular Cancer| Start Date: | End Date:

Program Affiliations

UCSF Liver Center

In the News

Mignote Yilma, M.D. to Join National Clinician Scholars Program at UCSF
December, 16, 2020 | UCSF General Surgery Residency Program
Study Shows Excellent Post-Transplant Outcomes Following Down-Staging of HCC Patients
December, 10, 2014 | UCSF Transplant Surgery

Research Narrative

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Research Interests

Hepatocellular carcinoma (HCC)

Liver transplantation outcomes including expanded criteria liver transplants

Cardiopulmonary complications of chronic liver disease

Liver injury and repair (Liver transplantation)

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 189
  1. Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified delphi panel.
    Singal AG, Quirk L, Boike J, Chernyak V, Feng Z, Giamarqo G, Kanwal F, Ioannou GN, Manes S, Marrero JA, Mehta N, Pillai A, Shaheen NJ, Shaukat A, Sirlin CB, Verna E, Wani S, Wilson Woods A, Yang JD, Parikh ND| | PubMed
  2. Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers.
    Norman JS, Li PJ, Kotwani P, Yao FY, Pham S, Gamez J, Mehta N| | PubMed
  3. Multi-HCC: A practical model to prioritize patients with hepatocellular carcinoma on the liver transplant waiting list.
    Norman J, Mehta N, Kim WR, Liang JW, Biggins SW, Asrani SK, Heimbach J, Charu V, Kwong AJ| | PubMed
  4. Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma.
    Zhou K, Nguyen L, Tabrizian P, Mehta N| | PubMed
  5. YTTRIUM-90 RADIOEMBOLIZATION HAS BECOME THE MOST UTILIZED BRIDGING TREATMENT FOR LIVER TRANSPLANT CANDIDATES IN THE UNITED STATES.
    Salem R, Kwong AJ, Kim N, Sze DY, Mehta N| | PubMed
  6. Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs.
    Singal AG, Kilgore KM, Shvets E, Parikh ND, Mehta N, Burak Ozbay A, Teigland C, Hafez O, Schroeder A, Yang A, Schinkel J| | PubMed
  7. Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort.
    Li Z, Chen IC, Centonze L, Magyar CTJ, Choi WJ, Shah S, O'Kane GM, Vogel A, De Carlis L, Lerut J, Lai Q, Mehta N, Chen CL, Sapisochin G| | PubMed
  8. Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma?.
    Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Yao, Vincenzo Mazzaferro, Josep M. Llovet| | UCSF Research Profile
  9. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.
    Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N| | PubMed
  10. Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System.
    Yilma M, Houhong Xu R, Saxena V, Muzzin M, Tucker LY, Lee J, Mehta N, Mukhtar N| | PubMed
  11. Recent Advances in Liver Transplantation for Hepatocellular Carcinoma.
    Li PJ, Shah S, Mehta N| | PubMed
  12. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC.
    Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG| | PubMed
  13. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Shravan D, Veeral A, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD| | PubMed
  14. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index.
    Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG| | PubMed
  15. Development and validation of a biomarker index for HCC treatment response.
    Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD| | PubMed
  16. Bridging the rural-urban gap in access to liver transplantation.
    Zhou K, Shah S, Thompson LK, Mehta N| | PubMed
  17. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation.
    Li M, Bhoori S, Mehta N, Mazzaferro V| | PubMed
  18. THU-470-YI Analysis of treatment benefits and prognostic factors for posttransplant hepatocellular carcinoma recurrence in a large Euro-American-Asian cohort.
    Zhihao Li, Itsuko Chih-Yi Chen, Grainne O'Kane, Arndt Vogel, Luciano De Carlis, Leonardo Centonze, Quirino Lai, Neil Mehta, Chao-Long Chen, Gonzalo Sapisochin| | UCSF Research Profile
  19. Role of biomarkers in the diagnosis and management of HCC.
    Al-Hasan M, Mehta N, Yang JD, Singal AG| | PubMed
  20. Barriers to liver transplant referral in safety net settings: A national provider survey.
    Hundt M, Chen A, Donovan J, Kim N, Yilma M, Tana M, Mehta N, Zhou K| | PubMed
  21. EP74 COMPARATIVE ANALYSIS OF RESPONSE RATE AND TIME TO PROGRESSION AMONG NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTHCARE SYSTEM IN NORTHERN CALIFORNIA.
    Xiaoran Li, Steven Lam, Belia O. Roybal, Sreepriya Balasubramanian, Varun Saxena, Monica Muzzin, Richie Houhong Xu, Farhad Ferzanegan, Robert Freed, Neil Mehta, Mignote Yilma, Jeffrey K. Lee, Brock A. Macdonald, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar| | UCSF Research Profile
  22. Tu1568 COMPARATIVE ANALYSIS OF THE SAFETY OF NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTH CARE SYSTEM IN NORTHERN CALIFORNIA.
    Steven Lam, Xiaoran Li, Belia O. Roybal, Nizar A. Mukhtar, Sreepriya Balasubramanian, Varun Saxena, Monica Muzzin, Richie Houhong Xu, Farhad Ferzanegan, Robert Freed, Neil Mehta, Mignote Yilma, Jeffrey K. Lee, Brock A. Macdonald, Krisna P. Chai, Suk I. Seo| | UCSF Research Profile
  23. Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC).
    Mehta N| | PubMed
  24. Abstract No. 158 Cost-Effectiveness Analysis of Resection, Ablation, and Radiation Segmentectomy for Solitary Hepatocellular Carcinoma = 3 cm with Curative Intent.
    X. Wu, P. Vakil, M. Heller, E. Lehrman, N. Fidelman, N. Mehta, R. Lokken| | UCSF Research Profile
  25. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities.
    Martin SP, Mehta N, Emamaullee J| | PubMed
  26. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    Norman JS, Mehta N| | PubMed
  27. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?"
    Norman JS, Mehta N| | PubMed
  28. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT, Behr SC, Ohliger MA, Fowler KJ, Gill RM, Fidelman N, Mehta N, Choi HH| | PubMed
  29. How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box.
    Wang M, Cedars MI, Mehta N, Sarkar M| | PubMed
  30. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
    Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N| | PubMed
  31. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant.
    Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N| | PubMed
  32. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma.
    Yilma M, Mehta N| | PubMed
  33. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
    Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N| | PubMed
  34. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.
    Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ, North American Living Liver Donor Innovation Group (NALLDIG)| | PubMed
  35. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome.
    Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R| | PubMed
  36. Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification.
    Norman J, Mehta N, Kwong A| | PubMed
  37. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals.
    Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K| | PubMed
  38. Geographic disparities in access to liver transplantation.
    Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N| | PubMed
  39. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH| | PubMed
  40. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies.
    Mehta N, Kelley RK, Yao FY| | PubMed
  41. 730 IMPACT OF SURVEILLANCE AND SOCIAL DETERMINANTS OF HEALTH ON TREATMENT RECEIPT AND HEALTHCARE COSTS IN PATIENTS WITH HCC.
    Amit G. Singal, Karl M. Kilgore, Elizabet Shvets, Neehar D. Parikh, Neil Mehta, Ahmet B. Ozbay, Christie Teigland, Omar Hafez, Amy L. Schroeder, Audrey Yang, Jill K. Schinkel| | UCSF Research Profile
  42. Tu1550 UTILITY OF A BIOMARKER-DERIVED SCORE FOR TREATMENT RESPONSE ASSESSMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.
    Jeff Liang, Po-Yi Li, Joshua S. Norman, Yee Hui Yeo, Hirsh D. Trivedi, Walid S. Ayoub, Alexander Kuo, Marc L. Friedman, Tsuyoshi Todo, Irene Kim, Georgios Voidonikolas, Todd Brennan, Steven Wisel, Kambiz Kosari, Rola Saouaf, Nicholas N. Nissen, Neil Mehta, Ju Dong Yang| | UCSF Research Profile
  43. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
    Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY| | PubMed
  44. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?
    Wu X, Lokken RP, Mehta N| | PubMed
  45. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection.
    Hoffman D, Shui A, Gill R, Syed S, Mehta N| | PubMed
  46. Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis.
    Rice BA, Mehta N, Grab J, Dodge JL, Sherman CB| | PubMed
  47. Abstract No. 251 ? FEATURED ABSTRACT Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for Downstaging of Hepatocellular Carcinoma Before Liver Transplant.
    X. Wu, A. Kwong, M. Heller, R. Lokken, N. Fidelman, N. Mehta| | UCSF Research Profile
  48. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.
    Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND| | PubMed
  49. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates.
    Wu X, Heller M, Kwong A, Fidelman N, Mehta N| | PubMed
  50. Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US.
    Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D| | PubMed
  51. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation.
    Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM| | PubMed
  52. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation.
    Giard JM, Dodge JL, Yao FY, Mehta N| | PubMed
  53. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study.
    Qureshy Z, Lokken RP, Kakar S, Grab J, Mehta N, Sarkar M| | PubMed
  54. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma.
    Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N| | PubMed
  55. Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
    Wang M, Sarkar M, Mehta N| | PubMed
  56. Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada.
    Ivanics T, Wallace D, Claasen MPAW, Patel MS, Brahmbhatt R, Shwaartz C, Prachalias A, Srinivasan P, Jassem W, Heaton N, Cattral MS, Selzner N, Ghanekar A, Morgenshtern G, Mehta N, Massie AB, van der Meulen J, Segev DL, Sapisochin G| | PubMed
  57. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM| | PubMed
  58. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
    Huang AC, Dodge JL, Yao FY, Mehta N| | PubMed
  59. Liver allocation policies for hepatocellular carcinoma have leveled the playing field-But who should be playing?
    Kwong AJ, Mehta N| | PubMed
  60. Awarding additional MELD points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the United States.
    Bernards S, Lee E, Leung N, Akan M, Gan K, Zhao H, Sarkar M, Tayur S, Mehta N| | PubMed
  61. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.
    Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG| | PubMed
  62. Abstract No. 261 Cost-effectiveness analysis of interventional liver-directed therapies for a single, small (< 3 cm) hepatocellular carcinoma in liver transplant candidates.
    X. Wu, M. Heller, A. Kwong, N. Fidelman, N. Mehta| | UCSF Research Profile
  63. Nodular Regenerative Hyperplasia After Liver Transplant; It's All in the Presentation.
    Chen AK, Lunow-Luke T, Yamaguchi S, Praglin C, Agudelo E, Mehta N, Dirks R, Braun HJ, Gardner JM, Roberts JP, Syed SM, Roll GR| | PubMed
  64. 531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT.
    Varun Saxena, Liyan Liu, Joanna B. Ready, Mai Sedki, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar, Sreepriya Balasubramanian, Brock A. Macdonald, Neil Mehta, Julie A. Schmittdiel| | UCSF Research Profile
  65. EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA.
    Mignote Yilma, Jackson Voelkel, Richie Houhong Xu, Leu-Yen Tucker, Monica Muzzin, Varun Saxena, Neil Mehta, Jeffrey K. Lee, Suk I. Seo, Brock A. Macdonald, Joanna B. Ready, Sreepriya Balasubramanian, Nizar A. Mukhtar| | UCSF Research Profile
  66. National experience with living donor liver transplantation for hepatocellular carcinoma.
    Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N| | PubMed
  67. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma.
    Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N| | PubMed
  68. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
    Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N| | PubMed
  69. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis.
    Yilma M, Saxena V, Mehta N| | PubMed
  70. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB| | PubMed
  71. National time trends in mortality and graft survival following liver transplantation from circulatory death or brainstem death donors.
    Wallace D, Cowling TE, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Ivanics T, Claasen M, Mehta N, Heaton N, van der Meulen J, Walker K| | PubMed
  72. Decreased Urgency Among Liver Transplantation Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ, Ghaziani TT, Mehta N| | PubMed
  73. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N| | PubMed
  74. Survival After Liver Transplantation: An International Comparison Between the United States and the United Kingdom in the Years 2008-2016.
    Ivanics T, Wallace D, Abreu P, Claasen MPAW, Callaghan C, Cowling T, Walker K, Heaton N, Mehta N, Sapisochin G, van der Meulen J| | PubMed
  75. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC| | PubMed
  76. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality?
    Mehta N, Yao FY| | PubMed
  77. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort.
    Reddy SHS, Mehta N, Dodge JL, Hakeem AR, Khorsandi SE, Jassem W, Vilca-Melendez H, Cortes-Cerisuelo M, Srinivasan P, Prachalias A, Heneghan MA, Aluvihare V, Suddle A, Miquel R, Rela M, Heaton ND, Menon KV| | PubMed
  78. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N| | PubMed
  79. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY| | PubMed
  80. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management.
    Mehta N| | PubMed
  81. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
    Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G| | PubMed
  82. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma.
    Harding-Theobald E, Yao FYK, Mehta N| | PubMed
  83. 433 THE ASSOCIATION OF SUSTAINED VIROLOGIC RESPONSE ON TREATMENT OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH HEPATITIS C.
    Neehar D. Parikh, Neil Mehta, Maarouf Hoteit, Ju Dong Yang, Binu V. John, Andrew M. Moon, Reena Salgia, Anjana A. Pillai, Ihab Kassab, Naba Saeed, Emil Thyssen, Piyush Nithani, Jeffrey Mckinney, Wesley Chan, Claire Durkin, Matthew Connor, Manaf Alsudaney, Brenda Durand, Nicholas N. Nissen, Hannah P. Kim, Raghavendra Paknikar, Nicole E. Rich, Matthew Schipper, Amit G. Singal| | UCSF Research Profile
  84. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma.
    Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N| | PubMed
  85. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study.
    Kotwani P, Chan W, Yao F, Mehta N| | PubMed
  86. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma.
    Yao FY, Fidelman N, Mehta N| | PubMed
  87. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis.
    Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N| | PubMed
  88. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.
    Deng LX, Mehta N| | PubMed
  89. Reply.
    Mehta N, Yao FY| | PubMed
  90. Opioid use prior to liver transplant is associated with increased risk of death after transplant.
    Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL| | PubMed
  91. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  92. Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse.
    Varun Saxena, Neil Mehta| | UCSF Research Profile
  93. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions.
    Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C| | PubMed
  94. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.
    Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG| | PubMed
  95. Social Media as an Early Proxy for Social Distancing Indicated by the COVID-19 Reproduction Number: Observational Study.
    Younis J, Freitag H, Ruthberg JS, Romanes JP, Nielsen C, Mehta N| | PubMed
  96. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit?
    Kwong A, Mehta N| | PubMed
  97. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival.
    Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM| | PubMed
  98. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G| | PubMed
  99. Recurrence of hepatocellular carcinoma following liver transplantation.
    Hoffman D, Mehta N| | PubMed
  100. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma.
    Weinfurtner K, Dodge JL, Yao FYK, Mehta N| | PubMed
  101. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
    Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN| | PubMed
  102. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient.
    Zhou K, Mehta N| | PubMed
  103. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK| | PubMed
  104. OPIOID USE PRIOR TO LIVER TRANSPLANT IS ASSOCIATED WITH INCREASED RISK OF DEATH AFTER TRANSPLANT.
    Hillary Braun, Marisa P. Schwab, Chengshi Jin, Dominic Amara, Trevor Grace, Rhiannon Croci, Chris E. Freise, John P. Roberts, Neil Mehta, Ryutaro Hirose, Nancy L. Ascher| | UCSF Research Profile
  105. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.
    Kalra A, Hawkins ES, Nowacki AS, Jain V, Milinovich A, Saef J, Thomas G, Gebreselassie SK, Karnik SS, Jehi L, Young JB, Svensson LG, Chung MK, Mehta N| | PubMed
  106. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier AH, Smith JD, Kalra A, Gebreselassie SK, Thomas G, Hawkins ES, Svensson LG| | PubMed
  107. THU248 Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage.
    George Therapondos, Brian Lee, Gene Im, John Rice, Ann Lazar, Michael R. Lucey, Ethan Weinberg, Hyosun Han, Haripriya Maddur, R. Mark Ghobrial, Christine Hsu, Oren Fix, Sheila Eswaran, Kirti Shetty, Neha Jakhete, David Victor, David Foley, Neil Mehta, Mary Rinella, Thomas Schiano, Constance Mobley, Norah Terrault| | UCSF Research Profile
  108. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
    Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N| | PubMed
  109. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.
    Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG| | PubMed
  110. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic.
    Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW| | PubMed
  111. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A| | PubMed
  112. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Lee E, Sarkar M, Dodge J, Kohi M, Mehta N| | PubMed
  113. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N| | PubMed
  114. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.
    Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C| | PubMed
  115. Hepatocellular Carcinoma-How to Determine Therapeutic Options.
    Mehta N| | PubMed
  116. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.
    Cullaro G, Rubin JB, Mehta N, Lai JC| | PubMed
  117. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N, Dodge JL, Grab JD, Yao FY| | PubMed
  118. REPLY.
    Mehta N, Dodge JL, Yao FY| | PubMed
  119. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
    Gutin L, Yao F, Dodge JL, Grab J, Mehta N| | PubMed
  120. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study.
    Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J| | PubMed
  121. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC| | PubMed
  122. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.
    Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG| | PubMed
  123. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F| | PubMed
  124. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
  125. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis.
    Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault| | UCSF Research Profile
  126. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning.
    Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J| | PubMed
  127. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?
    Mehta N, Yao FY| | PubMed
  128. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  129. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria.
    Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N| | PubMed
  130. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM| | PubMed
  131. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND| | PubMed
  132. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead.
    Mehta N, Monto A, Yao FY| | PubMed
  133. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.
    Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G| | PubMed
  134. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
  135. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma.
    Samoylova ML, Mehta N, Roberts JP, Yao FY| | PubMed
  136. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence.
    Roberts DE, Kakar S, Mehta N, Gill RM| | PubMed
  137. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes.
    Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N| | PubMed
  138. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA| | PubMed
  139. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  140. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis.
    Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA| | PubMed
  141. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection.
    E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta| | UCSF Research Profile
  142. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?.
    M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta| | UCSF Research Profile
  143. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.
    Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G| | PubMed
  144. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis.
    B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault| | UCSF Research Profile
  145. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?
    Mehta N, Yao FY| | PubMed
  146. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels.
    Azeem N, Ajmera V, Hameed B, Mehta N| | PubMed
  147. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin.
    Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J| | PubMed
  148. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  149. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
    Mehta N, Yao FY| | PubMed
  150. International Differences in the Risk of Death from Smoking and Obesity: The Case of the United States and Finland.
    Mehta N, Elo I, Stenholm S, Aromaa A, Heliövaara M, Koskinen S| | PubMed
  151. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY| | PubMed
  152. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  153. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY| | PubMed
  154. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
    Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D| | PubMed
  155. Acute liver injury in a Glatopa-treated patient with MS.
    Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC| | PubMed
  156. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC| | PubMed
  157. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY| | PubMed
  158. Screening for hepatocellular carcinoma: What is missing?
    Mehta NJ, Celik AD, Peters MG| | PubMed
  159. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)?
    Mehta N, Yao FY| | PubMed
  160. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
    Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium| | PubMed
  161. Reply.
    Mehta N, Yao FY| | PubMed
  162. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N| | PubMed
  163. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
    Mehta N, Roberts JP, Yao FY| | PubMed
  164. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis.
    Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV| | PubMed
  165. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival.
    G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant| | UCSF Research Profile
  166. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan.
    Mehta N, Yao FY| | PubMed
  167. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study.
    G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix| | UCSF Research Profile
  168. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition?
    Mehta N, Yao FY| | PubMed
  169. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY| | PubMed
  170. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
    Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY| | PubMed
  171. Abstract 19009: The Association Between Clinical and Echocardiographic Imaging Findings and T2* in End Stage Liver Disease.
    Gabriel Brooks, Kathryn Brown, Neil Mehta, Karen Ordovas, Nevah Rubin, Elyse Foster, Atif Qasim| | UCSF Research Profile
  172. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP| | PubMed
  173. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
    Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP| | PubMed
  174. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.
    Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N| | PubMed
  175. Response to letter to the editors.
    Yao FY, Hameed B, Mehta N, Roberts JP| | PubMed
  176. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY| | PubMed
  177. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?.
    M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts| | UCSF Research Profile
  178. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  179. BMJ endgames: a new web-based BMJ/JGIM collaboration.
    Srinivasan M, Mehta N| | PubMed
  180. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY| | PubMed
  181. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation.
    Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J| | PubMed
  182. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.
    Mehta N, Yao FY| | PubMed
  183. Reply: To PMID 23333661.
    Yao F, Mehta N| | PubMed
  184. Immunosuppression: Conventions and controversies.
    Mehta N, Hirose R| | PubMed
  185. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.
    Mehta N, Fidelman N, Sarkar M, Yao FY| | PubMed
  186. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization.
    Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff| | UCSF Research Profile
  187. Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy.
    Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD| | PubMed
  188. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
    Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR| | PubMed
  189. Intensity-modulated radiation therapy in gynecologic malignancies.
    Salama JK, Roeske JC, Mehta N, Mundt AJ| | PubMed